PROSPECTS FOR THE USE OF CONTRACEPTIVE VAGINAL PATCH ZB-06
Abstract
With the high frequency of unplanned pregnancies in many countries, there is an urgent need for more affordable and effective contraceptives. In recent years, scientists around the world have been actively developing new methods of barrier contraception. This method is very simple and convenient due to the fact that it has no systemic effect, side effects are minimized, and a woman can use it when she needs it. In order to fill the gap in this niche, scientists have developed the ZB-06 vaginal contraceptive film containing the HC4-N human contraceptive antibody (HPA).
Purpose. Study literature sources on the use of contraceptive vaginal film ZB-06.
Materials and methods. Materials from PubMed and PubMedCentral resources of the US National Library of Medicine, Google Scholar, Elsevier Clinical Key and Elsevier Science Direct were used to analyze the literature. For the analysis of scientific literature, a qualitative method based on content analysis was used, namely, the definition of units of analysis - headings, annotations and keywords of articles; calculation of the frequency and percentage distribution of analysis units by analysis categories using the Excel program; interpretation and generalization of analysis results.
Results. This review presents summarized research results that demonstrate that the ZB-06 contraceptive film has a number of advantages and disadvantages. This method of contraception provides effective levels of mucosal antisperm antibodies for at least 3 hours after use.
Conclusion. Contraceptive vaginal film ZB-06 is an innovative, non-hormonal, topically applied vaginal film (containing HC4-N PPA), which in phase 1 of the study showed a high level of effectiveness and met the safety requirements for contraceptives.
Downloads
References
An Exploratory Study of ZB-06 as a Vaginal Contraceptive Film, 2023. https://ichgcp.net/ru/clinical-trials-registry/NCT04731818
Muthusamy S., Varghese J., Raveendran V., Ezilarasan K., Easow J.M. Evaluation of interobserver reliability of Nugent score for diagnosis of bacterial vaginosis. Indian J Sex Transm Dis AIDS, 2018, vol. 39(2), pp. 120-123. https://doi.org/10.4103/ijstd.IJSTD_98_16
Notario-Pérez F., Cazorla-Luna R., Martín-Illana A., et al. Design, fabrication and characterisation of drug-loaded vaginal films: State-of-the-art. J Control Release. 2020, vol. 327, pp. 477-499. https://doi.org/10.1016/j.jconrel.2020.08.032
Shapiro R.L., DeLong K., Zulfiqar F., Carter D., Better M, Ensign L.M. In vitro and ex vivo models for evaluating vaginal drug delivery systems. Adv Drug Deliv Rev., 2022, vol. 191, 114543. https://doi.org/10.1016/j.addr.2022.114543
Adolescents and long-acting reversible contraception: implants and intrauterine devices. ACOG Committee Opinion No. 735. American College of Obstetricians and Gynecologists. Obstet Gynecol, 2018, vol. 131(5), pp. e130-e139. https://doi.org/10.1097/AOG.0000000000002632
Medical eligibility criteria for contraceptive use. World Health Organization. 5th ed., 2015, 210 p. https://www.who.int/publications/i/item/9789241549158
Polis C.B., Hussain R., Berry A. There might be blood: a scoping review on women’s responses to contraceptive-induced menstrual bleeding changes. Re-prod Health, 2018, vol. 15, article number: 114. https://doi.org/10.1186/s12978-018-0561-0
Akintomide H., Barnes P., Brima N., Mansour D. Higher discontinuation rate with a standard-sized compared to a small-sized ‘gold standard’ copper intrau-terine device: a case-control review. BMJ Sex Reprod Health, 2019, vol. 45, pp. 263-268. https://doi.org/10.1136/bmjsrh-2018-200296
World Contraceptive Use, 2022. https://www.un.org/en/development/desa/population/publications/dataset/contraception/wcu2018.asp
Smith-Mc Cune K., Chen J. C., Greenblatt R. M., et al. Unexpected Inflammatory Effects of Intravaginal Gels (Universal Placebo Gel and Nonoxynol-9) on the Upper Female Reproductive Tract: A Randomized Crossover Study. PLoS One, 2015, vol. 10(7), pp. 40-56. https://doi.org/10.1371/journal.pone.0129769
Musekiwa A., Fernando N.B., Abariga S.A. Effectiveness of vaginal microbicides in preventing HIV transmission. Trop Med Int Health, 2020, vol. 25(7), pp. 790-802. https://doi.org/10.1111/tmi.13401
Hasegawa A., Fu Y., Tsubamoto H., et al. Epitope analysis for human sperm-immobilizing monoclonal antibodies, MAb H6-3C4, 1G12 and campath-1. Mol Hum Reprod, 2003, vol. 9(6), pp. 337-343. https://doi.org/10.1093/molehr/gag045
Baldeon-Vaca, Marathe J.G., Politch J.A., et al. Production and characterization of a human antisperm monoclonal antibody against CD52g for topical contraception in women. EBioMedicine, 2021, vol. 69, p. 103478. https://doi.org/10.1016/j.ebiom.2021.103478
Politch J.A., Cu-Uvin S., Moench T.R., et al. Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): a phase I randomized trial. PLoS Med, 2021, vol. 18, pp. 20-27. https://doi.org/10.1371/journal.pmed.1003495
Han L., Padua E., Edelman A., Jensen J.T. Appraising cervical mucus: a new approach to evaluating contraceptives. Eur J Contracept Reprod Health Care. 2018, vol. 23(1), pp. 78-83. https://doi.org/10.1080/13625187.2018.1437134
Miller D. Review: The epic journey of sperm through the female reproductive tract. Animal, 2018, vol. 12(S1), pp. 110-S120. https://doi.org/10.1017/S1751731118000526
Mauck C.K., Vincent K.L. The postcoital test in the development of new vaginal contraceptives. Biol Reprod, 2020, vol. 103(2), pp. 437-444. https://doi.org/10.1093/biolre/ioaa099
Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, 2021. http://rsc.tech-res.com/clinical-research-sites/safety-reporting/daids-grading-tables
Manual for the standardization of colposcopy for the evaluation of vaginal products, Update 2000. World Health Organization. Accessed March 27, 2023. URL: https://apps.who.int/iris/handle/10665/67131
Nugent R.P., Krohn M.A., Hillier S.L. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol, 1991, vol. 29, pp. 297-301. https://doi.org/10.1128/jcm.29.2.297-301.1991
Kestelyn E., Agaba S., Van Nuil J. A randomised trial of a contraceptive vaginal ring in women at risk of HIV infection in Rwanda: Safety of intermittent and continuous use. PLoS One, 2018, vol. 13(6), e0197572. https://doi.org/10.1371/journal.pone.0197572
Ridgeway K., Montgomery E.T., Kevin Smith, Torjesen K., Ariane van der Straten, Sharon L., Griffin J. B. Vaginal ring acceptability: A systematic review and meta-analysis of vaginal ring experiences from around the world. Contraception, 2022, vol. 106, pp. 16-33. https://doi.org/10.1016/j.contraception.2021.10.001
Baldeon-Vaca G., Marathe J.G., Politch J.A., et al. Production and characterization of a human antisperm monoclonal antibody against CD52g for topical contraception in women. EBioMedicine, 2021, vol. 69, p. 103478. https://doi.org/10.1016/j.ebiom.2021.103478
Fichorova R.N., Mendonca K., Yamamoto H.S., Murray R., Chandra N., Doncel G.F. A quantitative multiplex nuclease protection assay reveals immunotoxicity gene expression profiles in the rabbit model for vaginal drug safety evaluation. Toxicol Appl Pharmacol, 2015, vol. 285, pp. 198-206. https://doi.org/10.1016/j.taap.2015.02.017
Zalenskaya I.A, Joseph T., Bavarva J., et al. Gene expression profiling of human vaginal cells in vitro discriminates compounds with pro-inflammatory and mucosa-altering properties: novel biomarkers for preclinical testing of HIV microbicide candidates. PLoS One, 2015, vol. 10, pp. 122-140. https://doi.org/10.1371/journal.pone.0128557
Copyright (c) 2024 Yuri A. Kucherenko, Daria S. Borisenko, Alexander E. Borisenko, Yulia A. Avdeeva, Alexey S. Kordysh
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
